Leonard Mazur - Citius Pharmaceuticals Chairman of the Board, Secretary
| CTXR Stock | USD 3.06 0.21 6.42% |
Chairman
Mr. Leonard L. Mazur is Executive Chairman of the Board, Secretary of the Company. Mr. Mazur is the Executive Chairman and Secretary of the Company and was a member of the Board since September 2014. Mr. Mazur is the cofounder and Vice Chairman of Akrimax Pharmaceuticals, LLC, a privately held pharmaceutical company specializing in producing cardiovascular and general pharmaceutical products. Akrimax was founded in September 2008 and has successfully launched prescription drugs while acquiring drugs from major pharmaceutical companies. From January 2005 to May 2012, Mr. Mazur also cofouned and served as the Chief Operating Officer of Triax Pharmaceuticals LLC, a specialty pharmaceutical company producing prescription dermatological drugs. Prior to joining Triax, he was the founder and, from 1995 to 2005, Chief Executive Officer of Genesis Pharmaceutical, Inc., a dermatological products company that marketed its products through dermatologists offices as well as copromoting products for major pharmaceutical companies. In 2003, Mr. Mazur successfully sold Genesis to Pierre Fabre, a leading pharmaceutical company. Mr. Mazur has extensive sales, marketing and business development experience from his tenures at Medicis Pharmaceutical Corporation as executive vice president, ICN Pharmaceuticals, Inc. as vice president, sales marketing, Knoll Pharma, and Cooper Laboratories, Inc. Mr. Mazur is a member of the Board of Trustees of Manor College, is a recipient of the Ellis Island Medal of Honor and was previously the chairman of the board of directors of LMB, the Companys whollyowned subsidiary since 2016.
| Age | 79 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Address | 11 Commerce Drive, Cranford, NJ, United States, 07016 |
| Phone | 908 967 6677 |
| Web | https://citiuspharma.com |
Leonard Mazur Latest Insider Activity
Tracking and analyzing the buying and selling activities of Leonard Mazur against Citius Pharmaceuticals stock is an integral part of due diligence when investing in Citius Pharmaceuticals. Leonard Mazur insider activity provides valuable insight into whether Citius Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Citius Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Citius Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Leonard Mazur over a month ago Disposition of 1165048 shares by Leonard Mazur of Citius Pharmaceuticals at 1.42 subject to Rule 16b-3 | ||
Leonard Mazur over two months ago Disposition of 2234700 shares by Leonard Mazur of Citius Pharmaceuticals at 0.77 subject to Rule 16b-3 | ||
Leonard Mazur over three months ago Acquisition by Leonard Mazur of 2234700 shares of Citius Pharmaceuticals at 0.8951 subject to Rule 16b-3 | ||
Leonard Mazur over six months ago Disposition of 1165048 shares by Leonard Mazur of Citius Pharmaceuticals at 1.42 subject to Rule 16b-3 |
Citius Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2474) % which means that it has lost $0.2474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4149) %, meaning that it created substantial loss on money invested by shareholders. Citius Pharmaceuticals' management efficiency ratios could be used to measure how well Citius Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 12/11/2024, Return On Tangible Assets is likely to drop to -0.88. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Citius Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 12/11/2024, Total Current Assets is likely to grow to about 41.5 M, while Non Currrent Assets Other are likely to drop slightly above 41.6 K.Similar Executives
| Found 3 records | CHAIRMAN Age | ||
| Douglas Treco | Inozyme Pharma | 66 | |
| Yves Sabbagh | Inozyme Pharma | N/A | |
| Lindsay Rosenwald | Fortress Biotech | 69 | |
Management Performance
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.25 |
Citius Pharmaceuticals Leadership Team
Elected by the shareholders, the Citius Pharmaceuticals' board of directors comprises two types of representatives: Citius Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Citius. The board's role is to monitor Citius Pharmaceuticals' management team and ensure that shareholders' interests are well served. Citius Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Citius Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Myron MD, Executive Officer | ||
| Dhananjay Wadekar, Senior Strategy | ||
| Leonard Mazur, Chairman of the Board, Secretary | ||
| Catherine MS, Executive Affairs | ||
| Jaime Bartushak, CFO, Principal Financial Officer | ||
| Nikolas Burlew, Executive Assurance | ||
| Ilanit Allen, Vice Communications | ||
| Myron Holubiak, President CEO, Director | ||
| Kelly Creighton, Manufacturing Chemistry | ||
| Gary Talarico, Executive Operations | ||
| Alan Lader, Senior Assurance |
Citius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Citius Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 9.61 M | ||||
| Shares Outstanding | 180.72 M | ||||
| Shares Owned By Insiders | 6.80 % | ||||
| Shares Owned By Institutions | 17.02 % | ||||
| Number Of Shares Shorted | 13.45 M | ||||
| Price To Earning | (1.34) X | ||||
| Price To Book | 0.32 X | ||||
| EBITDA | (36.73 M) |
Pair Trading with Citius Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
Moving against Citius Stock
| 0.86 | BMY | Bristol Myers Squibb | PairCorr |
| 0.84 | ESPR | Esperion Therapeutics | PairCorr |
| 0.75 | CAH | Cardinal Health | PairCorr |
| 0.67 | XAIR | Beyond Air | PairCorr |
| 0.65 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Citius Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Pharmaceuticals to buy it.
The correlation of Citius Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.